MedTrace Logo

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

NCT00863707 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 511

Last updated 2012-05-18

Study results available
· View outcomes & findings →

Summary

This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.

Conditions

Interventions

DRUG

Regadenoson

IV

DRUG

Placebo

IV

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Global Development

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863707 on ClinicalTrials.gov